Sign In
Buy TCRX
$0.743
-0.0127 (-1.68%)
At Close: Jul 31, 2026
TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock?
05:46am, Thursday, 07'th Nov 2024
TScan Therapeutics (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i
All TSC-treated patients were relapse-free and MRD negative as of data cutoff TSC-100 and TSC-101 demonstrate the potential to reduce relapse rates and increase relapse-free survival in patients with
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
09:05am, Friday, 04'th Oct 2024
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Thursday, 29'th Aug 2024
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates
09:15am, Monday, 12'th Aug 2024
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.51 per share a year ago.
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Monday, 12'th Aug 2024
FDA grants RMAT designation to TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning
TScan Therapeutics Announces Updates to its Board of Directors
07:00am, Friday, 14'th Jun 2024
Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
07:00am, Thursday, 30'th May 2024
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T ce
RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning RMAT designation granted for bo
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
09:15am, Monday, 13'th May 2024
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.93 per share a year ago.
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
07:00am, Monday, 13'th May 2024
First patient dosed in Phase 1 clinical trial for the treatment of solid tumors; initial data anticipated in 2024 All treatment-arm patients in the Phase 1 heme program remain relapse-free with no det
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
07:00am, Thursday, 09'th May 2024
Patient dosed with TSC-20 3 -A0201 targeting cancer-associated antigen PRAME On-track to report initial data from the solid tumor clinical trial in 2024 WALTHAM, Mass., May 09, 2024 (GLOBE NEWSWIRE) -
TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
11:06am, Wednesday, 01'st May 2024
TScan Therapeutics (TCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
04:05pm, Wednesday, 24'th Apr 2024
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T
TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares
11:03am, Wednesday, 24'th Apr 2024
WALTHAM, Mass., April 24, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T
